This suggests that drug-targeting the kinase that TLK2 encodes and/or the methyltransferase-like proteins that METTL2A/B encode may affect not only the pathogenesis but also the prognosis of GBM as well as the patient's response to chemotherapy. Here, METTL2A is linked to glioblastoma.